167P TisCRT-LAPC: A phase Ⅱ clinical trial of tislelizumab plus chemotherapy (nab-paclitaxel and gemcitabine, AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC). (December 2022) - Guo, X.; Zhou, Y.; Ji, Y.; Lou, W.; Wu, L.